Literature DB >> 22988874

Presynaptic dysfunction in Parkinson's disease: a focus on LRRK2.

Elisa Belluzzi1, Elisa Greggio, Giovanni Piccoli.   

Abstract

PD (Parkinson's disease) is a common neurodegenerative disease clinically characterized by bradykinesia, rigidity and resting tremor. Recent studies have proposed that synaptic dysfunction, implicated in numerous studies of animal models of PD, might be a key factor in PD. The molecular defects that lead to PD progression might be hidden at the presynaptic neuron: in fact accumulating evidence has shown that the majority of the genes linked to PD play a critical role at the presynaptic site. In the present paper, we focus on the presynaptic function of LRRK2 (leucine-rich repeat kinase 2), a protein that mutated represents the main genetic cause of familial PD described to date. Neurotransmission relies on proper presynaptic vesicle trafficking; defects in this process, variation in dopamine flow and alteration of presynaptic plasticity have been reported in several animal models of LRRK2 mutations. Furthermore, impaired dopamine turnover has been described in presymptomatic LRRK2 PD patients. Thus, given the pathological events occurring at the synapses of PD patients, the presynaptic site may represent a promising target for early diagnostic therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22988874     DOI: 10.1042/BST20120124

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  19 in total

1.  Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice.

Authors:  M Yue; K M Hinkle; P Davies; E Trushina; F C Fiesel; T A Christenson; A S Schroeder; L Zhang; E Bowles; B Behrouz; S J Lincoln; J E Beevers; A J Milnerwood; A Kurti; P J McLean; J D Fryer; W Springer; D W Dickson; M J Farrer; H L Melrose
Journal:  Neurobiol Dis       Date:  2015-03-31       Impact factor: 5.996

2.  Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents.

Authors:  Andrew B West; Rita M Cowell; João P L Daher; Mark S Moehle; Kelly M Hinkle; Heather L Melrose; David G Standaert; Laura A Volpicelli-Daley
Journal:  J Comp Neurol       Date:  2014-04-12       Impact factor: 3.215

3.  LRRKing up the right trees? On figuring out the effects of mutant LRRK2 and other Parkinson's disease-related genes.

Authors:  Heinz Steiner
Journal:  Basal Ganglia       Date:  2013-07-01

4.  LRRK2 Promotes Tau Accumulation, Aggregation and Release.

Authors:  Patrícia Silva Guerreiro; Ellen Gerhardt; Tomás Lopes da Fonseca; Mathias Bähr; Tiago Fleming Outeiro; Katrin Eckermann
Journal:  Mol Neurobiol       Date:  2015-05-27       Impact factor: 5.590

5.  Neurexin 2 p.G849D variant, implicated in Parkinson's disease, increases reactive oxygen species, and reduces cell viability and mitochondrial membrane potential in SH-SY5Y cells.

Authors:  Katelyn Cuttler; Dalene de Swardt; Lize Engelbrecht; Jurgen Kriel; Ruben Cloete; Soraya Bardien
Journal:  J Neural Transm (Vienna)       Date:  2022-10-15       Impact factor: 3.850

Review 6.  Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease.

Authors:  Kelly M Lohr; Shababa T Masoud; Ali Salahpour; Gary W Miller
Journal:  Eur J Neurosci       Date:  2016-09-02       Impact factor: 3.386

7.  G2019S LRRK2 and aging confer susceptibility to proteasome inhibitor-induced neurotoxicity in nigrostriatal dopaminergic system.

Authors:  Qian Xiao; Suosuo Yang; Weidong Le
Journal:  J Neural Transm (Vienna)       Date:  2015-08-08       Impact factor: 3.575

Review 8.  Vesicular integrity in Parkinson's disease.

Authors:  Shawn P Alter; Gina M Lenzi; Alison I Bernstein; Gary W Miller
Journal:  Curr Neurol Neurosci Rep       Date:  2013-07       Impact factor: 5.081

Review 9.  A visual review of the interactome of LRRK2: Using deep-curated molecular interaction data to represent biology.

Authors:  Pablo Porras; Margaret Duesbury; Antonio Fabregat; Marius Ueffing; Sandra Orchard; Christian Johannes Gloeckner; Henning Hermjakob
Journal:  Proteomics       Date:  2015-03-21       Impact factor: 3.984

Review 10.  LRRK2 and neuroinflammation: partners in crime in Parkinson's disease?

Authors:  Isabella Russo; Luigi Bubacco; Elisa Greggio
Journal:  J Neuroinflammation       Date:  2014-03-21       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.